 | • レポートコード：MRC2303J0090 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、236ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートによると、2021年に3,546.06百万ドルであった世界の片頭痛治療薬市場規模は、2022年に4,097.67百万ドルになり、2027年までにCAGR 15.73％で拡大して8,520.87百万ドルに達するとみられています。本書は、片頭痛治療薬の世界市場を対象とした調査結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療薬分類別（吐き気止め薬、血圧降下剤、麦角、オピオイド薬、鎮痛剤）分析、治療タイプ別（進行阻止、予防）分析、投与経路別（注射剤、鼻腔スプレー、経口剤）分析、流通別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、下記の項目を掲載しています。なお、本書内の企業情報としては、Aegis Therapeutics、Alder Biopharmaceuticals、Allergan、Eli Lilly、GlaxoSmithKline、Impax Laboratories、Johnson & Johnson、Luitpold Pharmaceuticals、Pfizer、TG Therapeutics、Winston Pharmaceuticalsなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の片頭痛治療薬市場規模：治療薬分類別 - 吐き気止め薬の市場規模 - 血圧降下剤の市場規模 - 麦角の市場規模 - オピオイド薬の市場規模 - 鎮痛剤の市場規模 ・世界の片頭痛治療薬市場規模：治療タイプ別 - 片頭痛進行阻止における市場規模 - 片頭痛予防における市場規模 ・世界の片頭痛治療薬市場規模：投与経路別 - 注射剤の市場規模 - 鼻腔スプレーの市場規模 - 経口剤の市場規模 ・世界の片頭痛治療薬市場規模：流通別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の片頭痛治療薬市場規模：地域別 - 南北アメリカの片頭痛治療薬市場規模 アメリカの片頭痛治療薬市場規模 カナダの片頭痛治療薬市場規模 ブラジルの片頭痛治療薬市場規模 ... - アジア太平洋の片頭痛治療薬市場規模 日本の片頭痛治療薬市場規模 中国の片頭痛治療薬市場規模 インドの片頭痛治療薬市場規模 韓国の片頭痛治療薬市場規模 台湾の片頭痛治療薬市場規模 ... - ヨーロッパ/中東/アフリカの片頭痛治療薬市場規模 イギリスの片頭痛治療薬市場規模 ドイツの片頭痛治療薬市場規模 フランスの片頭痛治療薬市場規模 ロシアの片頭痛治療薬市場規模 ... - その他地域の片頭痛治療薬市場規模 ・競争状況 ・企業情報 |
The Global Migraine Drugs Market size was estimated at USD 3,546.06 million in 2021 and expected to reach USD 4,097.67 million in 2022, and is projected to grow at a CAGR 15.73% to reach USD 8,520.87 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Migraine Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Therapeutic Class, the market was studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan.
Based on Treatment Type, the market was studied across Abortive and Preventive.
Based on Route of Administration, the market was studied across Injectable, Nasal Spray, and Oral.
Based on Distribution, the market was studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Migraine Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Migraine Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Migraine Drugs Market, including Aegis Therapeutics, Alder Biopharmaceuticals, Allergan, Eli Lilly, GlaxoSmithKline, Impax Laboratories, Johnson & Johnson, Luitpold Pharmaceuticals, Pfizer, TG Therapeutics, and Winston Pharmaceuticals.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Migraine Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Migraine Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Migraine Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Migraine Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Migraine Drugs Market?
6. What is the market share of the leading vendors in the Global Migraine Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Migraine Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of migraines and launch of new drugs
5.1.1.2. Rise in female population and increase in cigarette consumption
5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
5.1.2. Restraints
5.1.2.1. Side effects associated with migraine drugs
5.1.3. Opportunities
5.1.3.1. Supportive reimbursement policies for migraine medications
5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
5.1.4. Challenges
5.1.4.1. Availability of alternative therapies and regulatory challenges
5.2. Cumulative Impact of COVID-19
6. Migraine Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Anti-Nausea Drug
6.3.1. Chlorpromazine
6.3.2. Metoclopramide
6.3.3. Prochlorperazine
6.3. Blood Pressure Lowering Medication
6.4.1. Beta-Blocker
6.4.2. Calcium Channel Blocker
6.4. Ergots
6.5.1. Dihydroergotamines
6.5.2. Ergotamine
6.5.3. Lasmiditan
6.5. Opioid Medication
6.6.1. OxyContin
6.6.2. Percocet
6.6.3. Vicodin
6.6. Pain Reliever
6.7.1. Aspirin
6.7.2. Ibuprofen
6.7. Triptans
6.8.1. Rizatriptan
6.8.2. Sumatriptan
7. Migraine Drugs Market, by Treatment Type
7.1. Introduction
7.2. Abortive
7.3. Preventive
8. Migraine Drugs Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.3. Nasal Spray
8.4. Oral
9. Migraine Drugs Market, by Distribution
9.1. Introduction
9.2. Hospitals Based Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Americas Migraine Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Migraine Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Migraine Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Aegis Therapeutics
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Alder Biopharmaceuticals
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Allergan
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Eli Lilly
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. GlaxoSmithKline
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Impax Laboratories
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Johnson & Johnson
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Luitpold Pharmaceuticals
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Pfizer
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. TG Therapeutics
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Winston Pharmaceuticals
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing